Matthew Abernethy
Board Member
Fate Therapeutics Inc (FATE)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Matthew Abernethy
Matthew Abernethy is recorded as Board Member at Fate Therapeutics Inc (FATE). Fate Therapeutics Inc reported in an 8-K filed May 30, 2025 that Matthew Abernethy was appointed Class III director and member of the Audit Committee, effective May 29, 2025.
“On March 27, 2025, the board of directors (the “Board”) of Fate Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Matthew Abernethy to the Board to serve as a Class III director and member of the Audit Committee, in each case effective as of Mr. Abernethy’s election to the Board by the Company’s stockholders at the Annual Meeting of Stockholders held on May 29, 2025 (the “Annual Meeting”).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-05-29–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Fate Therapeutics Inc
Other people whose current roles at this company are on record from its filings.
- Bahram Valamehr CEO, Board Member
- Scott Wolchko CEO, Board Member
- William H. Rastetter Chairman
- J. Scott Wolchko CFO, Chief Accounting Officer
- Kamal Adawi CFO, Chief Accounting Officer
- Cindy R. Tahl General Counsel
- Edward J. Dulac III Chief Accounting Officer
- Karin Jooss Board Member
- Karin Jooss, Ph.D. Board Member
- Laura J. Hamill Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.